39
Participants
Start Date
October 8, 2020
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2027
Nivolumab
The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Ramucirumab
The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
RECRUITING
NYU Langone, New York
RECRUITING
Fox Chase Cancer Center, Philadelphia
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY
Fox Chase Cancer Center
OTHER